Supportive care in the patient with hormone refractory prostate cancer
Related Experiment Video
Updated: Oct 17, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
1Department of Hematology/Oncology, University of Michigan Comprehensive Cancer Center, Michigan Prostate Institute, Ann Arbor, USA.
Abstract:
Despite the advances being made in prostate cancer screening and early detection, a large percentage of patients will eventually be classified as "hormone refractory." Patients entering this phase are no longer curable, and therapies instituted in this setting are primarily palliative in nature. As a result, the onus on those working in the field of urologic oncology becomes managing the plethora of symptoms these patients experience as a result of both their disease and the treatment modalities used at this stage. The intent of this article is to provide an overview of some of these symptoms with guidelines for their management. Principles of pain management and additional manifestations requiring supportive care such as anorexia, constipation, anemia, urinary obstruction, and psychological concerns are discussed.
Related Concept Videos
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Treatment Resistant Cancers
Chronic Pancreatitis II: Collaborative Care
Assessment:
Disorders of the Male Reproductive System
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Heart Failure VI: Adjunct Therapies

